**Supplementary Table 7. Outcomes of HCC occurrence and survival through 36 weeks (intention-to-treat analysis)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Placebo group**  **(*n*=80)** | **YGJ group**  **(*n*=80)** | ***p-*value** |
| 24 weeks | HCC | 3 (3.8) | 2 (2.5) | 0.650 |
|  | Death, *n* (%) | 4 (5.0) | 4 (5.0) | > 0.999 |
|  | Variceal bleeding, *n* (%) | 1 (1.3) | 3 (3.8) | 0.311 |
|  | Liver transplantation, *n* (%) | 1 (1.3) | 2 (2.5) | 0.560 |
| 36 weeks | HCC, *n* (%) | 3 (3.8) | 3 (3.8) | > 0.999 |
|  | Death, *n* (%) | 7 (8.8) | 5 (6.3) | 0.548 |
|  | Variceal bleeding, *n* (%) | 4 (5.0) | 4 (5.0) | > 0.999 |
|  | Liver transplantation, *n* (%) | 1 (1.3) | 2 (2.5) | 0.560 |
|  | | | | |